InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,190.78
(
0.06%
)
US TECH 100
17,604.80
(
-0.05%
)
Dow Jones
39,084.98
(
0.52%
)
Brent Oil
83.55
(
0.83%
)
Bitcoin
62,296.04
(
-0.06%
)
Post# of 56
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

JohnCM

Send PM Follow Ignore
Followers 698
Posts 59465
Boards Moderated 18
Alias Born 06/01/2008

JohnCM

Re: None

Thursday, 07/23/2020 1:16:51 PM

Thursday, July 23, 2020 1:16:51 PM

Post# of 56

"We are pleased with the outcome of our recent interactions with the FDA, as they outline an efficient path to registration for etripamil which eliminates the need to start a new Phase 3 study," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent MIST News
More MIST News
InvestorsHub NewsWire

FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM

Start posting your company's news
Only $200 per official company press release!